Skip to content
drillr.ai
Sign up

NTRA

Natera, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$325.95
−0.52%
Ask drillr

  • Aug 28, 2026, 15:03 UTC

    Natera announced a national partnership with Susan G. Komen to accelerate breast cancer awareness and education, including efforts to increase understanding of minimal residual disease (MRD).

    Source:

  • Aug 27, 2026, 10:00 UTC

    Natera announced a collaboration with Angiex to use its Signatera test to assess response to Angiex's investigational antibody-drug conjugate AGX101 in a Phase I clinical trial.

    Source:

  • Aug 25, 2026, 09:29 UTC

    Callan Family Office LLC acquired a new position in Natera, Inc. by purchasing 3,582 shares valued at approximately $972,000 during the second quarter, as disclosed in a recent SEC filing.

    Source:

  • Aug 25, 2026, 07:55 UTC

    Brandywine Managers LLC acquired a new stake of 14,588 shares in Natera, Inc., valued at approximately $3,960,000, as disclosed in a Form 13F filing with the SEC.

    Source:

  • Aug 12, 2026, 10:00 UTC

    Natera announced a collaboration to support Kupando Therapeutics' Phase 1 clinical trial of KUP-101, using its Latitude assay to assess ctDNA dynamics in advanced skin cancers.

    Source:

  • Aug 7, 2026, 21:10 UTC

    Natera shares soared over 20% to an all-time high on August 7, 2026, boosting the co-founder's billionaire status.

    Source:

  • Aug 6, 2026, 20:05 UTC

    Natera reported financial results for the second quarter ended June 30, 2026, with total revenues of $752.8 million, up 37.7% year over year, and a gross margin of 64.5%.

    Source:

  • Aug 5, 2026, 10:00 UTC

    Natera submitted an application to Japan's PMDA for approval of its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.

    Source:

  • Jul 16, 2026, 22:35 UTC

    MolDx finalized a local coverage determination (LCD) that expands coverage for Natera's Prospera portfolio in the surveillance setting for solid organ allograft rejection.

    Source:

  • Jul 9, 2026, 10:00 UTC

    Natera announced that its Signatera test received IVDR certification as a Class C device under the European Union's In Vitro Diagnostic Regulation.

    Source:

  • Jul 1, 2026, 16:01 UTC

    Natera (NTRA) and Aveta Biomics have partnered to use Natera's Signatera test in a global Phase 3 trial for head and neck cancer to assess minimal residual disease and treatment response.

    Source:

  • Jun 29, 2026, 10:00 UTC

    Natera and Aveta Biomics announced a strategic partnership to support Aveta's global Phase 3 registrational trial of APG-157 in head and neck cancer.

    Source:

  • Jun 25, 2026, 11:00 UTC

    Natera and Eledon Pharmaceuticals announced a strategic partnership to incorporate Natera's Prospera test into Eledon's planned Phase 3 kidney transplant trial.

    Source:

  • Jun 24, 2026, 07:00 UTC

    Natera's Signatera test received regulatory approval from Japan's PMDA for colorectal cancer.

    Source:

  • Jun 23, 2026, 10:00 UTC

    NCCN updated its Bladder Cancer guidelines to recommend ctDNA-MRD testing using Natera's Signatera technology.

    Source:

  • Jun 5, 2026, 00:00 UTC

    Natera, Inc. appointed Thomas Lynch as a Class I Director and member of the Board, effective June 2, 2026.